By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Small Interference RNAs (siRNAs). According to news originating from Hangzhou, People's Republic of China, by NewsRx correspondents, research stated, "Aptamers are a class of oligonucleotides that can specifically bind to different targets with high affinity. Since their discovery in 1980s, aptamers have attracted considerable interests in medical applications."
Our news journalists obtained a quote from the research from Zhejiang University, "So far, initial research using aptamers as delivery systems has produced exciting results. In this review, we summarize recent progress in aptamer-mediated chemotherapeutic drug and siRNA delivery systems in tumor treatment. With regard to chemotherapeutic drugs, the 2 main methods for targeted delivery using aptamers are as follows: aptamer-drug systems (in which aptamers directly deliver the drug both as a carrier and as a ligand) and aptamer-nanoparticles systems (in which nanoparticles function together with aptamers for targeted delivery of drugs). For delivery of siRNA, aptamers can be utilized by the following ways to facilitate targeting: (1) linked by a connector; (2) form a chimera; and (3) combined with nanoparticles. In co-delivery system, the advantages associated with the use of aptamers are beginning to become apparent also."
According to the news editors, the research concluded: "Here, the challenges and new perspectives in the field of aptamer-mediated delivery have been discussed."
For more information on this research see: Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. Journal of Controlled Release, 2013;171(2):152-162. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news correspondents report that additional information may be obtained from X. Li, Zhejiang University, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, People's Republic of China. Additional authors for this research include Q.H. Zhao and L.Y. Qiu (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Asia, Cancer, Therapy, Hangzhou, Genetics, Oncology, Nanoparticle, Nanotechnology, Emerging Technologies, People's Republic of China, Small Interference RNAs (siRNAs)
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC